Acarix publishes a supplement to the prospectus

The board of directors of Acarix AB ("Acarix" or the "Company") has prepared a supplement to the
prospectus regarding invitation to acquire shares in the approved preferential rights issue in Acarix
which was approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) on 20
August, 2020 and published by the Company on the same date. The supplementary prospectus has
been prepared due to the information in the Company's press release on 2 September 2020
regarding the transfer of subscription rights from the two largest shareholders and the Company's
press release earlier today regarding the German Ministry of Health's statement that
phonocardiography for ruling out coronary artery disease has potential for general use in Germany


.Acarix_PR_prospectus_supplement (003)

Acarix_PM_offentliggörande_av_tilläggsprospekt (003)


About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit